肿瘤浸润 B 细胞抑制鼻咽癌转移
Tumor-infiltrating B cells inhibit nasopharyngeal carcinoma metastasis.
本研究表明,TIL-B在NPC的抗肿瘤免疫中发挥重要的调节作用,并提示其治疗潜力,为开发基于B细胞或靶向TLS的免疫治疗策略提供了依据。
英文原题:CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer.
我们的研究强调了CD8+ TILs在NPC中的预后价值,以及未来探索利用CD8+淋巴细胞的细胞免疫疗法的潜力。
TIL(肿瘤浸润淋巴细胞)是存在于肿瘤内的免疫细胞群,在抗原特异性宿主免疫应答中至关重要。在本研究中,我们旨在阐明CD3+、CD4+和CD8+ TIL在鼻咽癌(NPC)中的预后意义。
使用基于重排T细胞受体(TCR)读段的RNA测序(RNA-seq)数据以及利用表达数据估计恶性肿瘤中基质和免疫细胞的ESTIMATE免疫评分工具,对NPC样本(n = 50)中的免疫细胞浸润进行了定量。还通过对训练队列(n = 35)的福尔马林固定、石蜡包埋样本进行IHC染色,表征了TIL亚群群体的差异丰度,该训练队列是RNA-seq队列(n = 50)的一个子集。
在RNA-seq队列中,重排TCR读数较高的患者具有更优的5年和10年总生存期(OS;P < 0.001)以及无病生存期(DFS;P < 0.001)。同样,ESTIMATE免疫评分较高的患者具有更优的5年和10年OS(P = 0.024)和DFS(P = 0.007)。在训练队列中,CD8+ TIL高丰度与改善的5年和10年OS(P = 0.003)和DFS(P = 0.005)显著相关。这些发现在一个独立验证队列(n = 84)以及训练队列和验证队列的联合分析[n = 119(35+84)]中得到证实,后者进一步表明在局部区域控制(P < 0.001)和远处转移(P = 0.03)方面5年和10年生存期改善。
PURPOSE: Tumor-infiltrating lymphocytes (TIL) are immune cell populations found within tumors, critical in the antigen-specific host immune response. In this study, we aimed to elucidate the prognostic significance of CD3+, CD4+, and CD8+ TILs in nasopharyngeal cancer (NPC). EXPERIMENTAL DESIGN: Immune cell infiltration was quantified in NPC samples (n = 50) using RNA-sequencing (RNA-seq) data based on rearranged T-cell receptor (TCR) reads and the Estimation of Stromal and Immune cells in malignant tumors using expression data (ESTIMATE) immune score tool. The differential abundances of TIL subset populations were also characterized through IHC staining of formalin-fixed, paraffin-embedded samples from a training cohort (n = 35), which was a subset of the RNA-seq cohort (n = 50). RESULTS: In the RNA-seq cohort, patients with higher rearranged TCR reads experienced superior 5- and 10-year overall survival (OS; P < 0.001), and disease-free survival (DFS; P < 0.001). Similarly, patients with higher ESTIMATE immune scores experienced superior 5- and 10-year OS (P = 0.024) and DFS (P = 0.007). In the training cohort, high abundances of CD8+ TILs were significantly associated with improved 5- and 10-year OS (P = 0.003) and DFS (P = 0.005). These findings were corroborated in an independent validation cohort (n = 84), and combined analysis of the training and validation cohorts [n = 119 (35+84)], which further demonstrated improved 5- and 10-year survival in terms of locoregional control (P < 0.001) and distant metastasis (P = 0.03). CONCLUSIONS: Taken together, our study highlights the prognostic value of CD8+ TILs in NPC, and the potential of future investigations into cellular-based immunotherapies employing CD8+ lymphocytes.
MEMBER ACCOUNT
登录成功会直接打开下一页。